BridgeBio Pharma, Inc. (BBIO)
81.05
-0.45
(-0.55%)
USD |
NASDAQ |
Aug 24, 16:00
80.04
-1.01
(-1.25%)
After-Hours: 20:00
BridgeBio Pharma Enterprise Value : 18.61B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 18.61B |
| August 20, 2026 | 18.89B |
| August 19, 2026 | 19.09B |
| August 18, 2026 | 18.90B |
| August 17, 2026 | 18.29B |
| August 14, 2026 | 18.29B |
| August 13, 2026 | 18.55B |
| August 12, 2026 | 19.06B |
| August 11, 2026 | 19.04B |
| August 10, 2026 | 19.23B |
| August 07, 2026 | 19.19B |
| August 06, 2026 | 18.86B |
| August 05, 2026 | 18.70B |
| August 04, 2026 | 18.72B |
| August 03, 2026 | 18.31B |
| July 31, 2026 | 18.33B |
| July 30, 2026 | 18.73B |
| July 29, 2026 | 19.01B |
| July 28, 2026 | 19.40B |
| July 27, 2026 | 19.12B |
| July 24, 2026 | 19.10B |
| July 23, 2026 | 18.89B |
| July 22, 2026 | 18.83B |
| July 21, 2026 | 18.79B |
| July 20, 2026 | 18.46B |
| Date | Value |
|---|---|
| July 17, 2026 | 18.58B |
| July 16, 2026 | 18.37B |
| July 15, 2026 | 18.83B |
| July 14, 2026 | 19.11B |
| July 13, 2026 | 18.92B |
| July 10, 2026 | 19.46B |
| July 09, 2026 | 20.30B |
| July 08, 2026 | 17.99B |
| July 07, 2026 | 17.91B |
| July 06, 2026 | 17.87B |
| July 02, 2026 | 17.77B |
| July 01, 2026 | 17.24B |
| June 30, 2026 | 17.24B |
| June 29, 2026 | 16.55B |
| June 26, 2026 | 16.20B |
| June 25, 2026 | 16.09B |
| June 24, 2026 | 16.03B |
| June 23, 2026 | 15.89B |
| June 22, 2026 | 15.94B |
| June 18, 2026 | 15.42B |
| June 17, 2026 | 15.64B |
| June 16, 2026 | 15.50B |
| June 15, 2026 | 15.76B |
| June 12, 2026 | 15.53B |
| June 11, 2026 | 15.67B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Ionis Pharmaceuticals, Inc. | 10.03B |
| Pfizer Inc. | 211.77B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| BioMarin Pharmaceutical, Inc. | 16.25B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -155.89M |
| Revenue (Quarterly) | 243.68M |
| Total Expenses (Quarterly) | 395.89M |
| EPS Diluted (Quarterly) | -0.7775 |
| Gross Profit Margin (Quarterly) | 93.68% |
| Profit Margin (Quarterly) | -63.97% |
| Earnings Yield | -4.40% |
| Normalized Earnings Yield | -4.402 |